Drug research: Marketing before evidence, sales before safety;Arzneimittelforschung: Marketing vor evidenz, umsatz vor sicherheit

Deutsches Arzteblatt

Volumn 107, Issue 16, 2010, Pages 277-278

  Klemperer, David ^a  

^a UNIVERSITY OF APPLIED SCIENCES REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; RISPERIDONE; ROSIGLITAZONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EDITORIAL; HEART ARREST; PHARMACY; STROKE; WORLD HEALTH ORGANIZATION; ADVERSE DRUG REACTION; CLINICAL TRIAL (TOPIC); CONFLICT OF INTEREST; ECONOMICS; ETHICS; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; FRAUD; GERMANY; HUMAN; INFORMATION DISSEMINATION; MARKETING; MEDICAL ETHICS; PUBLISHING;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DRUG INDUSTRY; DRUG TOXICITY; ETHICS, PHARMACY; EVIDENCE-BASED MEDICINE; FRAUD; GERMANY; HUMANS; INFORMATION DISSEMINATION; MARKETING; PUBLICATION BIAS; RESEARCH SUPPORT AS TOPIC; RISPERIDONE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;

EID: 77952712611     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0277     Document Type: Editorial

References (10)

1. Heres S, Davis J, et al.: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163(2): 185-194 (Pubitemid 44480836)
2. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig W-D, Lieb K: The financing of drug trials by pharmaceutical companies and its consequences: part 1. a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials [Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen - Teil 1: Qualitative systematische Literaturübersicht zum Einfluss auf Studienergebnisse, -protokoll und -qualität[. Dtsch Arztebl Int 2010; 107(16): 279-285
3. Bekelman J E, Li Y, et al.: Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289(4): 454-465 (Pubitemid 36119966)
4. Ewart R, Lausen H, et al.: Undisclosed changes in outcomes in randomized controlled trials: an observational study. Ann Fam Med 2009; 7(6): 542-546
5. Topol EJ: Failing the public health - Rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351(17): 1707-1709 (Pubitemid 39383201)
6. Psaty BM, Kronmal RA: Reporting mortality findings in trials of rofecoxib for alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 2008; 299(15): 1813-1817
7. Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia. Prepared by the staff of the Committee on Finance, United States Senate, Max Baucus, Chairman, Chuck Grassley, Ranking Member. http://finance.senate.gov/press/ Gpress/2010/prg022010a.pdf. Accessed March 3, 2010.
8. Nissen SE: Setting the RECORD straight. JAMA 2010; 303(12): 1194-1195
9. Spielmans G, Parry P: From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Journal of Bioethical Inquiry 2010; 7: 13-29.
10. Dreier G, Hasselblatt H, Antes G, Schumacher M: Das Deutsche Register Klinischer Studien: Begründung, technische und inhaltliche Aspekte, internationale Einbindung. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2009; 52(4): 463-468